 |
 |
 |
 |
 |
 |
 |
 |
Zidovudine (AZT, Retrovir)
Overview
- A Clinical Overview of Zidovudine (AZT, Retrovir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Prescribing Information for Zidovudine (AZT, Retrovir) Oral Solution (PDF) (November 2006)
From GlaxoSmithKline - Prescribing Information for Zidovudine (AZT, Retrovir) IV Infusion (PDF) (October 2006)
From GlaxoSmithKline - Approval of Generic Zidovudine (September 20, 2005)
From U.S. Food and Drug Administration - Drug Interactions: Zidovudine (August 2004)
From Project Inform
News
- FDA Approves First Generic HIV/AIDS Drug in Capsule Form for United States Market (March 31, 2006)
From U.S. Food and Drug Administration - FDA Approves Four Generic Forms of Zidovudine for U.S. Sales After Retrovir's Patent Expires (September 21, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - GlaxoSmithKline's Patent on Retrovir Expires; Generic Versions of AZT Expected to Be Available Soon (September 20, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Zidovudine Generic Oral Solution Approved in United States (September 20, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - WHO Removes Cipla's Lamivudine, Zidovudine Generics From Approved Drug List (June 16, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Research
- Literature Citations for Zidovudine (Regularly Updated)
From U.S. National Institutes of Health - Clinical Trials Using Zidovudine (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Studies Raise Possible Long-Term Concern for Infants Exposed to Retrovir in Womb (April 16, 2007)
From aidsmap.com - HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO - Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - HIV-Positive Mothers Should Continue AZT Prophylaxis After Childbirth, Study Says (October 3, 2004)
A study finds a brief jump in breast milk viral load following AZT cessation.
From aidsmap.com - Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases - Mother-to-Child Transmission: How Will AZT and Nevirapine Use for MTCT Affect Future Treatment? (Winter 2003/2004)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - No PK Interaction Seen Between FTC and AZT or Tenofovir (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Nevirapine Reduced Mother-to-Child Transmission Better Than AZT -- At 70 Times Less Cost (September 12, 2003)
In AIDS Treatment News, from AIDS Treatment News - Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Intracellular Metabolism of AZT Leads to the Production of Significant Levels of d4T Triphosphate in HIV Infected Patients (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Nevirapine During Labor and in the Neonate Significantly Improves Zidovudine Prophylaxis for the Prevention of Perinatal HIV Transmission: Results of PHPT-2 First Interim Analysis (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO - Pharmacodynamic Effects of Zidovudine 600 mg Once Daily Versus Zidovudine 300 mg Twice Daily in Therapy-Naive HIV-Infected Patients (COD20002) (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO - Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Zidovudine and Lamivudine Seminal Plasma: Blood Plasma Concentration Ratios Do Not Predict Total SP Exposure (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - New Zidovudine-Resistant HIV Found in Treatment-Naive Patients (December 2001)
In HEPP News, from Brown Medical School - Phosphorylation of Zidovudine, Stavudine, and Abacavir in Peripheral Blood Mononuclear Cells in Treatment-Naive and Treatment-Experienced Patients (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Clinical Management
Clinical Management
  |
  |